Lack of nephrotoxic effects of the new quinolone antibacterial agent levofloxacin in rabbits.
The nephrotoxicity of (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1- piperazinyl)-7-oxo-7H-pyrido [1,2,3-de][1,4]benzoxazine-6-carboxylic acid hemihydrate (levofloxacin, DR-3355, CAS 100986-85-4), a new quinolone antibacterial agent, was evaluated in male New Zealand White (NZW) rabbits after oral administration of 30 or 120 mg/kg for 10 days. Although reduced body weight gain was observed in the 120 mg/kg, DR-3355 induced no change in function and morphology of the kidneys at both doses.
Inage
F
F
Drug Safety Research Center, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.
Kato
M
M
Yoshida
M
M
Akahane
K
K
Takayama
S
S
D000818:Animals; D000890:Anti-Infective Agents / Q000633:toxicity*; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000187:drug effects; D002509:Cephaloridine / Q000633:toxicity; D003404:Creatinine / Q000097:blood; D007674:Kidney Diseases / Q000139:chemically induced* / Q000473:pathology; D064704:Levofloxacin; D008297:Male; D015242:Ofloxacin / Q000633:toxicity*; D009929:Organ Size / Q000187:drug effects; D011817:Rabbits
D000890:Anti-Infective Agents; D064704:Levofloxacin; D015242:Ofloxacin; D003404:Creatinine; D002509:Cephaloridine